Skip to main content
AAO-HNSF 2024 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Panel Presentations

Rhinology/Allergy

Controversies in Medical and Surgical Management of Recalcitrant Chronic Rhinosinusitis: What Is the Evidence

Sunday, September 29, 2024
2:30 PM – 3:30 PM EDT
Location: MBCC, 230
CME/MOC Credit: 1
Disclosure(s):
Jivianne T. Lee, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Angela M. Donaldson, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Troy D. Woodard, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: Management of chronic rhinosinusitis (CRS) recalcitrant to medical and surgical intervention continues to be a challenge. Although recent years have witnessed significant expansion and innovation in our treatment armamentarium for refractory CRS, optimal application of available therapeutic options remains a subject of ongoing debate. The purpose of this panel presentation is to discuss current controversies in medical and surgical management of recalcitrant CRS, with a focus on recently introduced therapies and the relevant evidence. Emerging systemic biologics and their clinical efficacy for various CRS subtypes will be delineated. Controversial aspects of biologic therapy will be addressed; including indications, selection, timing, and tapering with a review of the pertinent literature. In addition, the role of topical antimicrobial agents and long-term macrolide therapy in refractory CRS will be discussed. Current formulations, protocols, risks, benefits, and arguments for and against such treatments will be elucidated along with the corresponding evidence. Furthermore, novel “big hole” endoscopic surgical approaches for management of recalcitrant CRS will be presented. The indications, techniques, and controversies involved with such revision surgical salvage procedures will be described in conjunction with video presentations. This session will be conducted by academic rhinologists using a multimedia, interactive case-based format with audience polling.

Learning Objectives:

  1. Recognize the evolving role of systemic biologics, emerging immunomodulators, topical antimicrobials, and long-term macrolides in treatment of recalcitrant chronic rhinosinusitis.
  2. Describe novel “big hole” revision endoscopic surgical procedures for management of refractory chronic rhinosinusitis; including indications, techhniques, and controversial aspects.
  3. Understand the current evidence, clinical efficacy, and optimal application of each therapeutic modality in patients with recalcitrant chronic rhinosinusitis.

    Moderator(s)

  • JL

    Jivianne T. Lee, MD

    Professor
    University of California Los Angeles
    Los Angeles, CA, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

    • Panelist(s)

  • JH

    Joseph K. Han, MD

    Chief of the Division of Rhinology
    EVMS Otolaryngology
    Virginia Beach, VA, United States

    Disclosure information not submitted.

  • Angela M. Donaldson, MD

    Associate Professor of Otolaryngology I Rhinology and Anterior Skull Base
    Mayo Clinic in Florida
    Jacksonville, FL, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • Troy D. Woodard, MD

    Professor Of Otolaryngology Head and Neck Surgery
    Cleveland Clinic
    Cleveland, OH, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.